MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) is advancing toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with an initial focus on industrial safety applications in South America’s mining sector. The company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, signaling a transition from technology development to field implementation in large enterprise environments.
Leyton brings extensive experience in national drug policy and workplace safety. He helped design and implement Chile’s 'Zero Tolerance' alcohol-impaired driving law as part of the country’s alcohol prevention framework and played a key role in establishing Chile’s roadside drug testing program introduced in 2019. His appointment reflects MindBio’s strategy of aligning technical development with regulatory and industry expertise in markets where impairment detection is closely tied to workplace safety and compliance requirements.
MindBio’s AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, relying solely on the human voice. The company is developing an enterprise platform including Edge-AI kiosks that integrate bespoke hardware and software for detecting drug and alcohol intoxication using voice and AI across various industries, including mining, aviation, construction, and law enforcement.
The move to commercialize this technology in South America is significant given the region’s large mining operations, where impairment poses serious safety risks. By leveraging Leyton’s expertise, MindBio aims to navigate complex regulatory environments and establish a foothold in markets where workplace safety standards are increasingly stringent. The company’s focus on voice-based detection offers a non-invasive, rapid, and scalable solution compared to traditional testing methods.
For more details, the full article can be accessed at https://ibn.fm/JBNVq. Information about MindBio Therapeutics is available in the company’s newsroom at https://ibn.fm/MBQIF.
